Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Share News (SHP)

  • There is currently no data for SHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Nikkei hobbled by trade worries, disappointing earnings

Wed, 15th May 2019 04:04

* Nikkei down slightly after 7 losing sessions

* Uncertainties over U.S.-China standoff keep investors onedge

* Takeda Pharma, Nissan sink after earnings shock

* Mitsubishi Estate jumps on share buyback, governancereform

By Hideyuki Sano

TOKYO, May 15 (Reuters) - Japanese share prices were cappedon Wednesday by concerns about the broader economic impact ofrising tensions between Washington and Beijing, while an arrayof disappointing corporate earnings added to the downcast mood.

The Nikkei share average was off 0.08% at 21,051,after spending much of the session under water, even after sevenstraight days of losses until Tuesday.

The broader Topix, which hit a four-month low theprevious day, was down 0.03% at 1534.51.

Trade-sensitive stocks came under pressure, even thoughglobal shares have somewhat stabilised after U.S. PresidentDonald Trump made optimistic comments on trade talks with China.

Trump insisted trade discussions with China had notcollapsed, denying talks with Beijing had broken down afterWashington punctuated two days of negotiations last week withanother round of tariffs on Chinese imports.

"Although we saw some recovery in share prices after Trump'scomments, there are heightened uncertainties over trade, whichare negative for stocks," said Shusuke Yamada, chief Japan FXand equity strategist at Bank Of America Merrill Lynch.

Steelmakers fell 2.4% while shippersdropped 0.9%.

Not helping sentiment was Japanese corporate earnings, withnet profits falling almost 5.0% from a year earlier inJanuary-March, according to Okasan Securities.

Takeda Pharmaceutical fell as much as 8.6%. Japan'sbiggest drugmaker forecast an unexpected operating loss for thecurrent year due to costs associated with the $59 billionpurchase of Shire Plc.

That helped to bring down Tokyo Stock Exchange's drugmakersubindex 3.1%, making it the worst performer.

Nissan Motor slumped as much as to 8.0% to itslowest levels since late December 2012, after the carmakerforecast the weakest profit outlook in more than a decade.

"The earnings results suggested that the company is in muchworse shape than I have imagined," said Hiroshi Masushima,market analyst at Monex Securities.

The carmaker, hit by former chairman Carlos Ghosn's arrestlast year and troubles at its North American business, also saidits dividend will be cut about 30% in another blow to investorsas its hefty payouts have been the only major attraction.

H2O Retailing fell as much as 12.7% to seven-yearlows as the mid-tier department store operator posted weakearnings and guidance.

On the upside, Mitsubishi Estate jumped as much as11.2% after the real estate developer announced its first sharebuyback and a plan to abolish anti-takeover steps.

Decliners slightly outnumbered advancers by 1065 to 992.(Editing by Shri Navaratnam)

More News
9 Nov 2016 13:58

Analysts pick winners as pharma sector bounces back on Clinton loss

(ShareCast News) - The pharmaceuticals sector bounced back after Donald Trump won the battle to become the next president of the United States and the Republican party won control of Congress, with analysts suggesting AstraZeneca, Shire and Eli Lilly were among the best placed stocks to capitalise o

Read more
9 Nov 2016 12:17

LONDON MARKET MIDDAY: US Stocks Pointed Lower After Trump's Victory

Read more
9 Nov 2016 09:58

Britain's FTSE dips after Trump win though pharma, gold miners surge

(ADVISORY- Follow European and UK stock markets in real time on the Reuters Live Markets blog on Eikon, see cpurl://apps.cp./cms/?pageId=livemarkets) * FTSE 100 down 0.1 pct * Gold miners, pharma stocks rally * U.S.-exposed firms also gain By Kit Rees LONDON, Nov 9 (

Read more
9 Nov 2016 09:20

Trump win boosts drug stocks as pricing fears recede

* Clinton was seen more likely to curb drug costs than Trump * California drug pricing move also heading for defeat By Ben Hirschler LONDON, Nov 9 (Reuters) - Pharmaceutical stocks surged in Europe on Wednesday as Republican Donald Trump's U.S. presidential election win led inve

Read more
3 Nov 2016 10:37

Broker tips: Shire, Next, Cineworld

(ShareCast News) - Credit Suisse downgraded retailer Next to 'underperform' from 'neutral' and slashed the price target to 4,600p from 4,950p. The bank said it was becoming increasingly cautious about Next's ability to stabilise margins in an environment of rising opex and input costs, and with bran

Read more
3 Nov 2016 09:33

Shire rallies on Merrill, Citi notes

(ShareCast News) - Shire got a boost on Thursday as Bank of America Merrill Lynch added the stock to its 'Europe 1' list with a 'buy' rating and 6,970p price target, saying the shares are too cheap. The bank pointed out that Shire shares have been weak since the third quarter results due to a 3% rev

Read more
2 Nov 2016 20:37

Adverse events in trial dent hopes for Roche haemophilia drug

LONDON, Nov 2 (Reuters) - Four patients have suffered serious adverse events in a clinical trial of an experimental haemophilia medicine from Roche, the Swiss group said on Wednesday, clouding prospects for its potential blockbuster product. The problems relate to thrombosis, or blood clots

Read more
1 Nov 2016 16:19

UPDATE 2-Shire slips on poor sales of haemophilia drugs

* Q3 revenue misses forecasts * Sales of Baxalta's haemophilia products disappoint * Company sticks to full-year earnings target * Shares recover some losses to trade down 1.5 pct (Adds quotes, reaction, updates shares) By Paul Sandle LONDON, Nov 1 (Reuters) - Shir

Read more
1 Nov 2016 12:18

Shire reiterates full-year guidance after in-line Q3

LONDON, Nov 1 (Reuters) - Drugmaker Shire met market expectations by reporting third-quarter earnings per share of $3.17, down 2 percent on a year ago due to extra shares issued when it bought haemophilia specialist Baxalta earlier this year. The London-listed group, which makes drugs to tr

Read more
1 Nov 2016 12:04

Shire slips on third-quarter earnings report

(ShareCast News) - Third-quarter revenues and earnings from Shire were just shy of forecasts, while the drug developer did not raise guidance as some had hoped, due to higher than expected costs from June's acquisition of Baxalta. Costs related to the licensing of its SHP647 drug for ulcerative coli

Read more
31 Oct 2016 14:32

Sector movers: Macquarie delivers boost for miners

(ShareCast News) - Media and mining stocks paced gains at the start of the week. Advertising colossus WPP reported that quarterly revenues grew 23.4%, with over 15 percentage points of that growth rate coming from currency translation effects as the pound weakened. Indeed, LFL net sales growth was

Read more
31 Oct 2016 14:23

FTSE 100 movers: Shire and Next sold off ahead of results

(ShareCast News) - The FTSE 100 was traipsing lower on Monday afternoon, led down by an assortment of companies across sectors, notably those that are due to report in the coming few days. Shire, which is scheduled to post its third-quarter results on Tuesday, was bottom of the pile as the drug deve

Read more
28 Oct 2016 16:33

Britain's FTSE edges higher as IAG boosts travel stocks

* FTSE 100 up 0.1 pct * IAG soars to 4-month high * RBS end lower in choppy trade after results (Recasts, adds detail and quote, updates prices at close) By Kit Rees and Alistair Smout LONDON, Oct 28 (Reuters) - Britain's top share index edged higher on Friday, led by a

Read more
27 Oct 2016 11:25

Shire Presents Phase II Maribavir Study Data At Conference

Read more
14 Oct 2016 12:54

Sector movers: Tesco leads cyclicals higher, pharma drags

(ShareCast News) - Cyclicals took over from defensives, with Tesco spearheading gains among food and drug retailers while pharma stocks acted as the main drag. Tesco shares accounted for the lion's share of the gains in that sector after Unilever said issues surrounding the supply of its leading bra

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.